Evidence map›Paper›PMID 36429078›Full record

ArticleCells2022

Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance.

Walid Al-Akkad, Pilar Acedo, Maria-Giovanna Vilia, Luca Frenguelli, Alexander Ney, Irene Rodriguez-Hernandez, Peter L Labib, Domenico Tamburrino, Gabriele Spoletini, Andrew R Hall and 14 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

Walid Al-AkkadUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0002-0109-3021
Pilar AcedoUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0003-4815-6090
Maria-Giovanna ViliaUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0002-0414-0727
Luca FrenguelliUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.
Alexander NeyUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0003-4868-2832
Irene Rodriguez-HernandezEngitix Therapeutics, The Westworks, 195 Wood Lane, Shepherd's Bush, London W12 7FQ, UK.
Peter L LabibUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0003-2362-9218
Domenico TamburrinoDivision of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK.
Gabriele SpoletiniDivision of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK.ORCID 0000-0002-6855-4515
Andrew R HallUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.
Simone CanestrariUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.
Anna OsnatoWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory, University of Cambridge, Cambridge CB2 0AW, UK.ORCID 0000-0001-5241-1512
Jose Garcia-BernardoWellcome Trust Sanger Institute, Hinxton, Cambridgeshire CB10 1RQ, UK.
Leinal SejourCancer Research Institute, HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Vessela VassilevaDepartment of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.ORCID 0000-0001-9917-1675
Ioannis S VlachosCancer Research Institute, HMS Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Giuseppe FusaiDivision of Surgery, Royal Free London NHS Foundation Trust, University College London, London NW3 2QG, UK.
Tu Vinh LuongUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0002-7598-7319
Steven R WhittakerEngitix Therapeutics, The Westworks, 195 Wood Lane, Shepherd's Bush, London W12 7FQ, UK.ORCID 0000-0001-9062-7947
Stephen P PereiraUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0003-0821-1809
Ludovic VallierWellcome Trust-MRC Cambridge Stem Cell Institute, Anne McLaren Laboratory, University of Cambridge, Cambridge CB2 0AW, UK.
Massimo PinzaniUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.
Krista RomboutsUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.ORCID 0000-0001-9440-0571
Giuseppe MazzaUCL Institute for Liver and Digestive Health, Royal Free Hospital, University College London, London NW3 2PF, UK.
The Royal Free Hospital · GBShepherd University · USRoyal Free London NHS Foundation Trust · GBBroad Institute · USWellcome/MRC Cambridge Stem Cell Institute · GBImperial College London · GBWellcome Sanger Institute · GB

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/N001540/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T2T0419Pancreatic Cancer UK RG2014_01_PERERIA
6 · The paper itself

Abstract

Over 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed at a late stage and are locally advanced or with concurrent metastases. The aggressive phenotype and relative chemo- and radiotherapeutic resistance of PDAC is thought to be mediated largely by its prominent stroma, which is supported by an extracellular matrix (ECM). Therefore, we investigated the impact of tissue-matched human ECM in driving PDAC and the role of the ECM in promoting chemotherapy resistance. Decellularized human pancreata and livers were recellularized with PANC-1 and MIA PaCa-2 (PDAC cell lines), as well as PK-1 cells (liver-derived metastatic PDAC cell line). PANC-1 cells migrated into the pancreatic scaffolds, MIA PaCa-2 cells were able to migrate into both scaffolds, whereas PK-1 cells were able to migrate into the liver scaffolds only. These differences were supported by significant deregulations in gene and protein expression between the pancreas scaffolds, liver scaffolds, and 2D culture. Moreover, these cell lines were significantly more resistant to gemcitabine and doxorubicin chemotherapy treatments in the 3D models compared to 2D cultures, even after confirmed uptake by confocal microscopy. These results suggest that tissue-specific ECM provides the preserved native cues for primary and metastatic PDAC cells necessary for a more reliable in vitro cell culture.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsCell Line, TumorExtracellular MatrixHumansPancreas3D cell-culturechemoresistanceextracellular matrixliver metastasispancreatic ductal adenocarcinomatissue engineeringtissue-specificity

Identifiers

PMID36429078
PMCPMC9688243
OpenAlexW4309463303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.